Determining whether Globus Medical (GMED) is undervalued involves evaluating its current share price against key financial metrics such as price-to-earnings ratios, projected earnings per share growth, and free cash flow generation. Bulls argue that strong organic revenue growth, expanding adjusted EBITDA margins, and successful integration of major corporate acquisitions justify higher valuations. Conversely, conservative analysts point out that premium trading multiples leave little margin for execution errors, making thorough fundamental research necessary before drawing conclusions.